Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $25.9 million.

  • Editas Medicine's Net Cash Flow fell 1749.55% to $25.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.6 million, marking a year-over-year increase of 41609.0%. This contributed to the annual value of $7.9 million for FY2024, which is 14414.66% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Net Cash Flow is $25.9 million, which was down 1749.55% from -$150000.0 recorded in Q2 2025.
  • In the past 5 years, Editas Medicine's Net Cash Flow ranged from a high of $215.2 million in Q1 2021 and a low of -$138.3 million during Q3 2023
  • In the last 5 years, Editas Medicine's Net Cash Flow had a median value of -$150000.0 in 2025 and averaged $1.3 million.
  • Per our database at Business Quant, Editas Medicine's Net Cash Flow surged by 480461.2% in 2021 and then crashed by 43479.17% in 2023.
  • Over the past 5 years, Editas Medicine's Net Cash Flow (Quarter) stood at -$56.4 million in 2021, then decreased by 22.74% to -$69.2 million in 2022, then soared by 159.43% to $41.1 million in 2023, then decreased by 13.15% to $35.7 million in 2024, then fell by 27.47% to $25.9 million in 2025.
  • Its Net Cash Flow was $25.9 million in Q3 2025, compared to -$150000.0 in Q2 2025 and $7.2 million in Q1 2025.